- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Neogenomics Inc.
Headquarters: Fort Myers, FL, United States
Website: http://www.neogenomics.com
Year Founded: 2001
Status: Public
Industry Sector: HealthServices
CEO: Anthony P. Zook
Number Of Employees: 2,200
Enterprise Value: $2,305,813,840
PE Ratio: -11.88
Exchange/Ticker 1: NASDAQ:NEO
Exchange/Ticker 2: N/A
Latest Market Cap: $934,049,792
BioCentury | Jan 11, 2025
Management Tracks
Faces in new places ahead of JPM: Rubin joining Guggenheim
Week’s management moves include new venture partners at Frazier and updates from Beigene, Intellia and more
BioCentury | Sep 26, 2024
Management Tracks
Century names CFO, CSO
Plus: Freenome’s CEO Nolan resigns and updates from NextRNA and Abiologics
BioCentury | Apr 30, 2024
Management Tracks
New CEOs at Evox and George Medicines
Plus: Stoke hires Thomas Leggett as CFO, and updates from TScan, Rinri, Tevogen and more
BioCentury | Apr 19, 2024
Management Tracks
Domain, Initial among quartet of biotechs unveiling CEOs
Plus: Jim Jenson becomes CEO of Morphoceuticals, and updates from Xeno, NeoGenomics, DeepUll and Verastem
BioCentury | Oct 21, 2023
Management Tracks
Daly to succeed McEnany as Catalyst CEO
Plus: Hennemand joins Covant as CEO and updates from Invitae, Immunome, Antiva, Omeros, Actimed and RegCell
BioCentury | Oct 19, 2022
Management Tracks
New chairs at SomaLogic, Anjarium
Plus Dechamps becomes CEO at Bioxodes, and updates from Abalos, M2Gen and Orion
BioCentury | Apr 22, 2022
Discovery & Translation
Genentech and Repare updates; plus an eye gland organoid and more
BioCentury’s roundup of translational news
BioCentury | May 8, 2021
Management Tracks
Turnstone announces Burgess’ move to executive chairman alongside pair of promotions; plus Fulgent, Centene FDS, Akouos and more
Turnstone Biologics Inc. President of R&D Mike Burgess will become executive chairman of R&D. The cancer immunotherapy company also promoted José Otero to CTO from SVP of
BioCentury | Mar 23, 2021
Management Tracks
Brainard to succeed Hallal as AlloVir CEO; plus Illumina, NeoGenomics, Nordic Nanovector, Abeona, Delix and more
Diana Brainard will become CEO of AlloVir Inc. (NASDAQ:ALVR), succeeding David Hallal who will become executive chairman. Brainard is SVP and head of the virology therapeutic area at Gilead Sciences
BioCentury | Feb 6, 2020
Management Tracks
BioMarin CFO steps down; plus Atara, Epirium, Abalos, CytomX and more
Items per page:
1 - 10 of 54